310 related articles for article (PubMed ID: 33822774)
1. The pyruvate kinase activator mitapivat reduces hemolysis and improves anemia in a β-thalassemia mouse model.
Matte A; Federti E; Kung C; Kosinski PA; Narayanaswamy R; Russo R; Federico G; Carlomagno F; Desbats MA; Salviati L; Leboeuf C; Valenti MT; Turrini F; Janin A; Yu S; Beneduce E; Ronseaux S; Iatcenko I; Dang L; Ganz T; Jung CL; Iolascon A; Brugnara C; De Franceschi L
J Clin Invest; 2021 May; 131(10):. PubMed ID: 33822774
[TBL] [Abstract][Full Text] [Related]
2. Pyruvate kinase activators: targeting red cell metabolism in thalassemia.
Kuo KHM
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):114-120. PubMed ID: 38066911
[TBL] [Abstract][Full Text] [Related]
3. Mitapivat for sickle cell disease and thalassemia.
Pilo F; Angelucci E
Drugs Today (Barc); 2023 Mar; 59(3):125-134. PubMed ID: 36847623
[TBL] [Abstract][Full Text] [Related]
4. Bitopertin, a selective oral GLYT1 inhibitor, improves anemia in a mouse model of β-thalassemia.
Matte A; Federti E; Winter M; Koerner A; Harmeier A; Mazer N; Tomka T; Di Paolo ML; De Falco L; Andolfo I; Beneduce E; Iolascon A; Macias-Garcia A; Chen JJ; Janin A; Lebouef C; Turrini F; Brugnara C; De Franceschi L
JCI Insight; 2019 Nov; 4(22):. PubMed ID: 31593554
[TBL] [Abstract][Full Text] [Related]
5. Mitapivat improves ineffective erythropoiesis and iron overload in adult patients with pyruvate kinase deficiency.
van Beers EJ; Al-Samkari H; Grace RF; Barcellini W; Glenthøj A; DiBacco M; Wind-Rotolo M; Xu R; Beynon V; Patel P; Porter JB; Kuo KHM
Blood Adv; 2024 May; 8(10):2433-2441. PubMed ID: 38330179
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of heme oxygenase ameliorates anemia and reduces iron overload in a β-thalassemia mouse model.
Garcia-Santos D; Hamdi A; Saxova Z; Fillebeen C; Pantopoulos K; Horvathova M; Ponka P
Blood; 2018 Jan; 131(2):236-246. PubMed ID: 29180398
[TBL] [Abstract][Full Text] [Related]
7. Elevated CDKN1A (P21) mediates β-thalassemia erythroid apoptosis, but its loss does not improve β-thalassemic erythropoiesis.
Liang R; Lin M; Menon V; Qiu J; Menon A; Breda L; Arif T; Rivella S; Ghaffari S
Blood Adv; 2023 Nov; 7(22):6873-6885. PubMed ID: 37672319
[TBL] [Abstract][Full Text] [Related]
8. Modified activin receptor IIB ligand trap mitigates ineffective erythropoiesis and disease complications in murine β-thalassemia.
Suragani RN; Cawley SM; Li R; Wallner S; Alexander MJ; Mulivor AW; Gardenghi S; Rivella S; Grinberg AV; Pearsall RS; Kumar R
Blood; 2014 Jun; 123(25):3864-72. PubMed ID: 24795345
[TBL] [Abstract][Full Text] [Related]
9. Ferroportin inhibitor vamifeport ameliorates ineffective erythropoiesis in a mouse model of β-thalassemia with blood transfusions.
Kalleda N; Flace A; Altermatt P; Ingoglia G; Doucerain C; Nyffenegger N; Dürrenberger F; Manolova V
Haematologica; 2023 Oct; 108(10):2703-2714. PubMed ID: 37165842
[TBL] [Abstract][Full Text] [Related]
10. Erythroferrone exacerbates iron overload and ineffective extramedullary erythropoiesis in a mouse model of β-thalassemia.
Olivera J; Zhang V; Nemeth E; Ganz T
Blood Adv; 2023 Jul; 7(14):3339-3349. PubMed ID: 36995275
[TBL] [Abstract][Full Text] [Related]
11. Mitapivat versus Placebo for Pyruvate Kinase Deficiency.
Al-Samkari H; Galactéros F; Glenthøj A; Rothman JA; Andres O; Grace RF; Morado-Arias M; Layton DM; Onodera K; Verhovsek M; Barcellini W; Chonat S; Judge MP; Zagadailov E; Xu R; Hawkins P; Beynon V; Gheuens S; van Beers EJ;
N Engl J Med; 2022 Apr; 386(15):1432-1442. PubMed ID: 35417638
[TBL] [Abstract][Full Text] [Related]
12. Erythrocyte pyruvate kinase activation in red cell disorders.
Matte A; Federti E; De Franceschi L
Curr Opin Hematol; 2023 May; 30(3):93-98. PubMed ID: 36853806
[TBL] [Abstract][Full Text] [Related]
13. Oral ferroportin inhibitor ameliorates ineffective erythropoiesis in a model of β-thalassemia.
Manolova V; Nyffenegger N; Flace A; Altermatt P; Varol A; Doucerain C; Sundstrom H; Dürrenberger F
J Clin Invest; 2019 Dec; 130(1):491-506. PubMed ID: 31638596
[TBL] [Abstract][Full Text] [Related]
14. Mitapivat, a pyruvate kinase activator, improves transfusion burden and reduces iron overload in β-thalassemic mice.
Mattè A; Kosinski PA; Federti E; Dang L; Recchiuti A; Russo R; Siciliano A; Riccardi V; Janin A; Mucci M; Leboeuf C; Iolascon A; Brugnara C; De Franceschi L
Haematologica; 2023 Sep; 108(9):2535-2541. PubMed ID: 36794508
[No Abstract] [Full Text] [Related]
15. Right in time: Mitapivat for the treatment of anemia in α- and β-thalassemia.
Musallam KM; Taher AT; Cappellini MD
Cell Rep Med; 2022 Oct; 3(10):100790. PubMed ID: 36260990
[TBL] [Abstract][Full Text] [Related]
16. Exogenous iron increases hemoglobin in beta-thalassemic mice.
Ginzburg YZ; Rybicki AC; Suzuka SM; Hall CB; Breuer W; Cabantchik ZI; Bouhassira EE; Fabry ME; Nagel RL
Exp Hematol; 2009 Feb; 37(2):172-83. PubMed ID: 19059700
[TBL] [Abstract][Full Text] [Related]
17. Mitapivat: A Quinolone Sulfonamide to Manage Hemolytic Anemia in Adults With Pyruvate Kinase Deficiency.
Wills J; Horenstein M; Kim A; Silva MA; Dima L
Am J Ther; 2023 Sep-Oct 01; 30(5):e433-e438. PubMed ID: 37713687
[TBL] [Abstract][Full Text] [Related]
18. Safety and Efficacy of Mitapivat in Pyruvate Kinase Deficiency.
Grace RF; Rose C; Layton DM; Galactéros F; Barcellini W; Morton DH; van Beers EJ; Yaish H; Ravindranath Y; Kuo KHM; Sheth S; Kwiatkowski JL; Barbier AJ; Bodie S; Silver B; Hua L; Kung C; Hawkins P; Jouvin MH; Bowden C; Glader B
N Engl J Med; 2019 Sep; 381(10):933-944. PubMed ID: 31483964
[TBL] [Abstract][Full Text] [Related]
19. Improvement of erythropoiesis in beta-thalassemic mice by continuous erythropoietin delivery from muscle.
Bohl D; Bosch A; Cardona A; Salvetti A; Heard JM
Blood; 2000 May; 95(9):2793-8. PubMed ID: 10779423
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in adults with non-transfusion dependent α-thalassaemia or β-thalassaemia: an open-label, multicentre, phase 2 study.
Kuo KHM; Layton DM; Lal A; Al-Samkari H; Bhatia J; Kosinski PA; Tong B; Lynch M; Uhlig K; Vichinsky EP
Lancet; 2022 Aug; 400(10351):493-501. PubMed ID: 35964609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]